Akeso: clinical-trial pipeline
Akeso is the sponsor of 156 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 84 are not yet finished and 3 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Trials by phase
| Phase | Trials |
|---|---|
| Phase 2 | 51 |
| Phase 1/2 | 37 |
| Phase 3 | 35 |
| Phase 1 | 32 |
| Not applicable | 1 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 59 |
| Recruiting | 41 |
| Not yet recruiting | 23 |
| Active, not recruiting | 20 |
| Terminated | 8 |
| Unknown | 5 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 110 |
| Gastroenterology and liver | 26 |
| Immunology and rheumatology | 19 |
| Dermatology | 16 |
| Women's health and obstetrics | 9 |
| Cardiovascular | 8 |
| Respiratory | 4 |
| Metabolic and endocrine (diabetes, obesity) | 2 |
| Neurology | 2 |
| Rare and genetic diseases | 2 |
| Nephrology and urology | 1 |
Countries
| Country | Trials |
|---|---|
| China | 145 |
| Australia | 7 |
| United States | 5 |
| Poland | 2 |
| Brazil | 1 |
| Canada | 1 |
| Germany | 1 |
| Spain | 1 |
| France | 1 |
| Italy | 1 |
| New Zealand | 1 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-20 | New trial posted | A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis. |
| 2026-10-15 | New trial posted | A Trial to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Spontan… |
| 2026-09-29 | New trial posted | A Study of AK157D1 for Injection in Advanced Solid Tumors |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT06984718 | A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC | Phase 2 | Recruiting | Spain, France, Italy, Poland |
| NCT06591520 | AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer | Phase 3 | Active, not recruiting | China |
| NCT06646055 | AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer | Phase 1/2 | Active, not recruiting | China |
| NCT07700979 | Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolu… | Phase 3 | Recruiting | China, Germany, Poland, United States |
| NCT05382442 | A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | Phase 2 | Active, not recruiting | China, United States |
| NCT05489289 | A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection | Phase 3 | Recruiting | China |
| NCT07619001 | A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations | Phase 1 | Not yet recruiting | China |
| NCT06371157 | A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Partici… | Phase 3 | Recruiting | China |
| NCT05689853 | Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors | Phase 1/2 | Recruiting | China |
| NCT06860789 | AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) | Phase 1 | Not yet recruiting | China |
| NCT06166888 | A Study of AK131 in Patients With Advanced Solid Tumors | Phase 1 | Recruiting | China |
| NCT07114315 | A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer | Phase 2 | Recruiting | China |
| NCT07755371 | A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal P… | Phase 2 | Not yet recruiting | China |
| NCT05960955 | Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Jun… | Phase 2 | Recruiting | China |
| NCT05229497 | A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors | Phase 1/2 | Active, not recruiting | China |
| NCT04982237 | A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Re… | Phase 3 | Active, not recruiting | China |
| NCT06730386 | A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors | Phase 1 | Recruiting | Australia |
| NCT06530251 | A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) | Phase 1/2 | Recruiting | China |
| NCT07566247 | A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor | Phase 1 | Not yet recruiting | China |
| NCT05951608 | A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors | Phase 1/2 | Active, not recruiting | China |
| NCT06387420 | A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia | Phase 1/2 | Not yet recruiting | China |
| NCT07623356 | A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer | Phase 1/2 | Recruiting | China |
| NCT07412613 | Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon… | Phase 3 | Recruiting | China |
| NCT07263919 | Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carci… | Phase 2 | Recruiting | China |
| NCT07023315 | A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/… | Phase 3 | Recruiting | China |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Akeso clinical trials: 84 open, 35 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/akeso/, data as of 2026-10-25.